Recordati.
Italian pharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 20
What's happening
One to three months ago
Gone quiet
No new reports in 90+ days-
Ionis Pharmaceuticals licensed Zilganersen to Recordati, which is now undergoing international regulatory filings and FDA review.Some support1 report
-
Recordati held its Board of Directors meeting in Milan on July 30, 2025, as a licensing agreement strengthened its SPC business in Europe.Some support2 reports
-
Merck announced the acquisition of Verona, while Recordati reported royalty earnings and Ligand Pharmaceuticals updated its CEO.Some support3 reports
No events began in the chosen period. Widen it, or reset.
Around Recordati this week
News at the entities that move Recordati most-
FDA StructuralNeurogene Inc. developed a gene therapy for Rett syndrome and received FDA agreement for a registrational trial design.Moves Recordati
-
board of directors StructuralThe company's board of directors declared a cash dividend on April 11, 2024.Moves Recordati
-
Moderna OperationalModerna and BioNTech are recognized as leaders in the personalized cancer vaccine space.Moves Recordati
-
Europe Shared contextFinancial globalization effects are positive across regions, with long-run green investment strongest in Europe.Moves Recordati
-
Milan Shared contextThe Italian government, led by Giorgia Meloni, deployed soldiers to Milan in response to ongoing civil unrest.Moves Recordati
Connections
The 8 strongest of 20, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Amarin (United Kingdom) Operational
Recordati and Amarin established a partnership for the exclusive licensing and commercialization of Vazkepa in the EU.
-
Ionis Pharmaceuticals Transactional
Ionis licensed Zilganersen to Recordati.
-
FDA Structural
Recordati operates under the formal regulatory oversight of the FDA for market access in the United States.
-
board of directors Structural
Recordati operates under the formal governance structure of its board of directors, which approves interim financial statements.
-
Moderna Operational
The companies are engaged in a strategic collaboration focused on shared research and commercialization goals.
-
Laura Broutier Transactional
Recordati provides a €250,000 research grant to support Laura Broutier's DISARMS project.
-
Europe Shared context
Recordati conducts licensing and commercialization activities within the European market.
-
Milan Shared context
Recordati conducts its corporate activities, such as board meetings and publishing statements, within Milan.
History
Events by the month they beganSeptember 2026
1 eventJuly 2026
1 eventJune 2026
3 events- Ionis Pharmaceuticals licensed Zilganersen to Recordati, which is now undergoing international regulatory filings and FDA review.
- Recordati held its Board of Directors meeting in Milan on July 30, 2025, as a licensing agreement strengthened its SPC business in Europe.
- Merck announced the acquisition of Verona, while Recordati reported royalty earnings and Ligand Pharmaceuticals updated its CEO.